Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TYRA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTyra Biosciences separates accounting officer role, promotes Julia Rueb from CFO duties
Filed April 2, 2026 · Period ending April 1, 2026 · ~1 min read
Key Changes
-
low
Julia Rueb, VP of Finance, designated as principal accounting officer effective April 1, 2026, taking over accounting responsibilities from CFO Alan Fuhrman who retains principal financial officer role.
Item 5.02 verify on EDGAR → -
low
Rueb has been with Tyra since October 2022, serving as Corporate Controller before promotion to VP Finance in January 2024; she is a CPA with prior Ernst & Young experience in life sciences.
Item 5.02 verify on EDGAR →
Summary
Tyra Biosciences filed a routine organizational disclosure splitting the principal accounting officer role from the CFO position. Julia Rueb, who has been VP of Finance since January 2024 and previously served as Corporate Controller, now holds the principal accounting officer designation. CFO Alan Fuhrman continues as principal financial officer but no longer carries the accounting officer title.
This type of role separation is common at growing companies as they formalize financial reporting structures. Rueb's progression from Controller to VP Finance to principal accounting officer reflects normal career advancement for someone with her background. The change appears procedural rather than indicative of any financial reporting concerns or CFO transition.
Retail investors should view this as administrative housekeeping with no immediate impact on operations or strategy. Watch for the company's next quarterly filing to confirm smooth financial reporting under the new structure.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
On April 1, 2026, the Board of Directors of Tyra Biosciences, Inc. (the Company) designated Julia Rueb, Vice President, Finance of the Company, as the Company’s principal accounting officer, succeeding Alan Fuhrman, the Company’s Chief Financial Officer, in that role, each effective as of April 1, 2026. Mr. Fuhrman continues to be the Company’s principal financial officer.
The Board separated the principal accounting officer role from the CFO position. Julia Rueb, who has been VP of Finance since January 2024 and previously served as Corporate Controller, now holds the principal accounting officer title. CFO Alan Fuhrman retains the principal financial officer designation but no longer serves as principal accounting officer.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify